ARUP Institute for Clinical & Experimental Pathology®

Created in 1996, the ARUP Institute for Clinical and Experimental Pathology® seeks to expand the quantity, quality, and utility of laboratory medicine. Since its inception, the institute has developed approximately 620 tests that ARUP now performs in-house. Of these 620 tests, more than 400 were developed by institute scientists, while more than 200 others were improved and validated so that ARUP could perform them in-house rather than continue to refer them out. Moreover, ARUP research scientists have shared their knowledge, experience, and new developments with the scientific community by publishing more than 1,600 original peer-reviewed research publications in leading journals.

The institute’s mission is to be at the forefront of innovative research and development in clinical and experimental laboratory medicine and to continually contribute to the profession.

Research Focus

The institute's focus covers the spectrum of medical laboratory medicine:

Executive Directors

Julio Delgado, MD, MS
Co-Executive Director
(801) 583-2787

 

Sherrie L. Perkins, MD, PhD
Co-Executive Director
(801) 581-5854

Project Categories

The ARUP Institute for Clinical and Experimental Pathology® sponsors projects within four broad categories: creating new laboratory tests; improving current clinical laboratory tests; evaluating and critiquing tests, including alpha- and beta-site protocols; and conducting basic and clinical research projects. Research performed on human subjects is conducted under informed consent following the protocols approved by the University of Utah Institutional Review Board (IRB).


 

Recent Publications

Chen ZW, Perkins SL, Weiss RL, Bahler DW, Hussong JW, Salama ME. A limited plasma cell flow cytometry panel with reflex CD138 immunohistochemistry is an optimal workflow process for evaluating plasma cell neoplasms in bone marrow specimens. Am J Clin Pathol2015;143(1):78–83.

Lee M, Keener J, Xiao J, Long Zheng X, Rodgers GM. ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci 2015;72(2):349–56.

Greene DN, Vaughn CP, Crews BO, Agarwal AM. Advances in detection of hemoglobinopathies. Clinica Chemica Acta 2015;439C:50–57.

Javan H, Szuscik AM, Li L, Schaaf CL, Salama ME, Selzman CH. Cardiomyocyte p65 NF–kB is necessary for compensatory adaptation to pressure–overload. Circ Heart Fail 2015;8(1):109–18.

Grenache DG, Heichman KA, Werner TL, Vucetic Z. Clinical performance of two multi–marker blood tests for predicting malignancy in women with an adnexal mass. Clinica Chimica Acta 2015;438:358–63.

Sergueeva AI, Miasnikova GY, Polyakova LA, Nouraie M, Prchal JT, Gordeuk VR. Complications in children and adolescents with Chuvash polycythemia. Blood 2015;125(2):414–5.

Samowitz WS. Evaluation of colorectal cancers for Lynch syndrome: practical molecular diagnostics for surgical pathologists. Mod Pathol2015;28 Suppl 1:S109–13.